April 16, 2025 10:38 AM EDT
News Briefing

No­var­tis ter­mi­nates knee pain study; Telix re­ports brain tu­mor da­ta

ENDPOINTS

Plus, news about Tiger Gene and Ther­at­e­ch­nolo­gies:

No­var­tis scraps knee pain drug: The Swiss drug­mak­er dis­con­tin­ued a

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

In a blow to its obe­si­ty pipeline, Pfiz­er drops oral drug af­ter liv­er in­jury case

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times